Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 7/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | METAP2 | P50579 | 4/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PRKX | P51817 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.45 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13750190 | 0.90 | MAPK1 (0.44) | HSD17B10RAB9ASMN1; SMN2NPC1TSHR | |
| SCHEMBL13870209 | 0.82 | RECQL (0.54) | RAB9ASMN1; SMN2NPC1METAP2HPGD | |
| SCHEMBL14027386 | 0.82 | MAPK1 (0.59) | RAB9ASMN1; SMN2NPC1METAP2ROCK2 | |
| SCHEMBL13870208 | 0.80 | HPGD (0.50) | RAB9ASMN1; SMN2ALOX15NPC1HPGD | |
| SCHEMBL8445012 | 0.80 | NPC1 (0.57) | RAB9ASMN1; SMN2NPC1METAP2TSHR | |
| SCHEMBL13778173 | 0.80 | DAO (0.50) | RAB9ASMN1; SMN2NPC1TSHRDAO | |
| SCHEMBL9851981 | 0.78 | L3MBTL1 (0.54) | RAB9ASMN1; SMN2TSHRCDC7DBF4 | |
| SCHEMBL4330308 | 0.78 | NPC1 (0.36) | HSD17B10RAB9ASMN1; SMN2NPC1TSHR | |
| SCHEMBL14050074 | 0.77 | CDC7 (0.53) | RAB9ATSHRCDC7DBF4DAO | |
| SCHEMBL28733047 | 0.76 | CDC7 (0.48) | SMN1; SMN2CDC7DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716915-A | Chemical mechanical polishing solution | 安集微电子科技（上海）股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-110878087-B | Shenqinmycin triazole derivative and preparation method and application thereof | 长江大学 | 2021-04-09 | — | — | CN | claimed |
| CN-110878087-A | Shenqinmycin triazole derivative and preparation method and application thereof | 长江大学 | 2020-03-13 | — | — | CN | claimed |
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-07-09 | — | — | US | disclosed |
| US-12012392-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-06-18 | — | — | US | disclosed |
| US-11613542-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2023-03-28 | — | — | US | disclosed |
| US-11530200-B2 | Compounds | INFLAZOME LIMITED (IE) | 2022-12-20 | — | — | US | disclosed |
| US-11530200-B2 | Compounds | INFLAZOME LIMITED (IE) | 2022-12-20 | — | — | US | disclosed |
| CN-114716915-A | Chemical mechanical polishing solution | 安集微电子科技（上海）股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220106289-A1 | NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-04-07 | — | — | US | disclosed |
| US-20220106289-A1 | NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-04-07 | — | — | US | disclosed |
| EP-1258480-A1 | Pharmaceutical use of N-Carbamoylazole derivatives | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| US-5510320-A | EXCELLENT CONTROL OF BLACKGRASS AND WILD OATS AND OTHER WEEDS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-04-23 | — | — | US | disclosed |
| EP-0610314-A1 | HERBICIDAL TRIAZOLECARBOXAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-08-17 | — | — | EP | disclosed |
| WO-1993021164-A1 | HERBICIDAL TRIAZOLESULFONATES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993009100-A1 | HERBICIDAL TRIAZOLECARBOXAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-05-13 | — | — | WO | disclosed |
| EP-0487084-A2 | Image forming method and apparatus | CANON KABUSHIKI KAISHA (JP) | 1992-05-27 | — | — | EP | disclosed |
| US-4363915-A | PRE-EMERGENT | GULF OIL CORPORATION (US) | 1982-12-14 | — | — | US | disclosed |
| EP-0045566-A2 | Benzylsulfonyl diethylcarbamyl triazole and use as a selective herbicide | Gulf Oil Corporation (US) | 1982-02-10 | — | — | EP | disclosed |
| US-4280831-A | Benzylsulfonyl diethylcarbamyl triazole and use as a selective herbicide | GULF OIL CORPORATION (US) | 1981-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | HSD17B10 967/4885RAB9A 3901/4885SMN1; SMN2 3567/4885 |
| US-20220106289-A1 | NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | HSD17B10 1106/4885RAB9A 4107/4885SMN1; SMN2 4051/4885 |
| US-11530200-B2 | Compounds | NLRP3, NOD1, NLRP1 | HSD17B10 853/4885RAB9A 2907/4885SMN1; SMN2 4271/4885 |
| US-12012392-B2 | Sulfonamide carboxamide compounds | NLRP3, PYCARD, NOD1 | HSD17B10 1106/4885RAB9A 4158/4885SMN1; SMN2 2459/4885 |
| US-11613542-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | HSD17B10 1558/4885RAB9A 2868/4885SMN1; SMN2 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.